ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer
Daisuke Kotani(National Cancer Center Hospital East), Aldo Scarpa(University of Verona), David K. Chang(University of Glasgow), Yoshiaki Nakamura(National Cancer Center Hospital East), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Raphael Koch, Christian Pilarsky(University Hospital Carl Gustav Carus), Steven Gallinger(Ontario Institute for Cancer Research), Nikolajs Zeps, Khawla S. Al‐Kuraya(King Faisal Specialist Hospital & Research Centre), Naoya Sakamoto(Chibaken Saiseikai Narashino Hospital), Keunchil Park(The University of Texas MD Anderson Cancer Center), Jean Abraham, Mark A. Rubin(University of Bern), Amber L. Johns(Garvan Institute of Medical Research), Hideaki Bando(Aichi Cancer Center), Rita T. Lawlor(University of Verona), Sun-Soo Yoon, Rebecca C. Fitzgerald(Cancer Research UK), Tatsuhiro Shibata(The University of Tokyo), Olivier Elemento(Cornell University), Lincoln Stein(National Cancer Center Hospital East), Takayuki Yoshino(University of Tsukuba), Takao Fujisawa(Osaka Prefectural Medical Center), S. Nikolaev, Wai Sang Poon(Prince of Wales Hospital), Marco A. Marra(University of British Columbia), Jan O. Korbel(European Bioinformatics Institute), David A. Tuveson(Cold Spring Harbor Laboratory), Raffaella Casolino(University of Verona), Carlos Caldas(University of Cambridge), Andrew V. Biankin(University of Glasgow), Xiaojian Wu(Guangxi Academy of Agricultural Science), Eun Sook Lee(National Cancer Center), Jianmin Wu, Lorenz Trümper(University of Göttingen), Paul Brennan(Centre international de recherche sur le cancer), Qimin Zhan(Peking University)
Cited by 3
Related Papers
A global reference for human genetic variation
|Nature|2015|20.3k
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k